Definitive agreement to accelerate adoption of Renalytix’s FDA-approved, Medicare reimbursed kidneyintelX.dkd test to slow kidney disease progression and improve patient outcomes
Renalytix collaborates with NYKHM to bring kidneyintelX.dkd testing to underserved communities in the Greater New York area, enabling access for over 2,000 patients.
Company has Achieved Prerequisites for Growing Test Adoption with FDA Authorization, Clinical Outcomes Data, Inclusion in Clinical Guidelines, and Broad Insurance Coverage
Guidelines highlight the importance of risk prediction and personalized treatment to reduce risk
Local Coverage Determination would result in contracted coverage for an estimated additional five million Medicare patients with Type 2 diabetes and early-stage chronic kidney disease
US Patent Office Allows Patent Claims for Intellectual Property Exclusively Licensed to Renalytix
World leading, multi-disciplinary experts advise on adoption of FDA authorized KidneyintelX.dkd across 14 million US patients with diabetes and chronic kidney disease
Distribution agreement opens kidneyintelX.dkd testing to address early-stage kidney disease in region with one of the highest incidence rates for type 2 diabetes globally
Renalytix announces a c.$20.3 million private placement
Award for consortium of industry, academic and clinical research leaders to develop personalized drug response tests in chronic kidney disease
Significant milestone will make KidneyIntelX accessible to 960,000 veterans with chronic kidney disease
Renalytix announced its full year results for the twelve months ended 30 June 2022.